Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756712 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL7932653 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL314542 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL259446 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL6725190 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL14131245 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL24146779 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL13461111 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL10040218 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL278293 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216340-A1 | A Nucleoside Derivative For Use As A Drug, Particularly For The Treatment Of Chronic Lymphocytic Leukemia | INST BIOLOGII MEDYCZNEJ POLSKIEJ AKADEMII NAUK (PL) | 2017-08-03 | — | — | US | disclosed |
| WO-2016020858-A2 | A NUCLEOSIDE DERIVATIVE FOR USE AS A DRUG, PARTICULARLY FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA | INSTYTUT BIOLOGII MEDYCZNEJ POLSKIEJ AKADEMII NAUK (PL) | 2016-02-11 | — | — | WO | disclosed |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | BARRE LOUISA | 2010-11-18 | — | — | US | disclosed |
| EP-0967220-B1 | Novel arabinosyladenine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6242429-B1 | ANTIVIRAL ARA-A DERIVATIVES HAVING RESISTANCE TO METABOLISM BY ADENOSINEDEAMINASE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-0967220-A1 | Novel arabinosyladenine derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1999-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216340-A1 | A Nucleoside Derivative For Use As A Drug, Particularly For The Treatment Of Chronic Lymphocytic Leukemia | ENTPD5, DCTD, TYMP | ADORA3 266/4885LMNA 1543/4885NT5E 50/4885 |
| US-20100290990-A1 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF | TPMT, NUDT1, DUT | ADORA3 92/4885LMNA 3403/4885NT5E 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.